Halozyme Therapeutics Inc. (NASDAQ: HALO) stock declined by 0.15% at last close whereas the HALO stock gains by 10.04% in the pre-market trading session. Halozyme is a pharmaceutical business that develops revolutionary ways to enhance patient outcomes and experiences for both new and current medicines.
>> 7 Top Picks for the Post-Pandemic Economy <<
HALO stock, Financial Highlights
Halozyme Therapeutics reported its second-quarter 2021 financial results. Here’s the summary:
Discover Tomorrow's Stocks Today!
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
- The revenue generated for the second quarter of 2021 was $136.5 million relative to $55.2 million for Q2 2021.
- The second quarter’s cost of product sales was $23.0 million whereas for the second quarter 2020 it was $5.7 million
- The research and development costs for Q2 2021 were $8.1 million, relative to $9.0 million in the second quarter of 2020.
- For the second quarter of 2021 selling, general, and administrative costs were $12.3 million while the values were $11.0 million in the second quarter of 2020.
- Operating income was $93.0 million on a GAAP basis in the second quarter of 2021, relative to $29.6 million in the second quarter of 2020.
- Net income was $91.5 million on a GAAP basis in the second quarter of 2021, relative to $25.8 million in Q2 of 2020.
- The non-GAAP net income in the second quarter of 2021 was $97.8 million, relative to $33.6 million in the second quarter of 2020.
- On June 30, 2021, cash, cash equivalents, and marketable securities totaled $755.3 million, up from $368.0 million on December 31, 2020.
Read More
Corporate Update
In the second quarter, HALO repurchased about 1.0 million shares of common stock for $48.8 million at an average value of $47.05, meeting its objective of $125 million in share repurchases at an average price of $44.43 in 2021.
HALO stock 2021 Financial Expectations
- Revenues are expected to be between $425 million to $445 million, a rise from the previous estimate of $375 to $395 million, reflecting a 59% to 66% year-over-year increase.
- GAAP Operating Income is anticipated between $260 million to $280 million, an increase of 80 percent to 94 percent year over year.
- GAAP Diluted Earnings per Share of $1.55 to $1.70, up from an earlier forecast of $1.25 to $1.40, reflecting 70 percent to 86 percent year-over-year increase.
- Non-GAAP Diluted Earnings per Share of $1.85 to $2.00, up from an earlier forecast of $1.55 to $1.70, representing 65% to 78% year-over-year increase.